2017 Press Releases

Press Releases | In the News

This section and the included press releases are presented for historical purposes only. Press releases and other documents speak only as of the date thereof.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle
01/27/17Novan Reports Topline Results from SB204 Phase 3 Pivotal Trials
Topical Acne Product Candidate Achieves Statistical Significance on All Three Co-Primary Endpoints in One Trial, Demonstrates Statistical Significance on Only One of Three in the Second Company Continues to Analyze Trial Data to Better Understand These Results MORRISVILLE, N.C., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ:NOVN) today announced  top-line results from the Company’s two, replicate Phase 3 pivotal clinical trials for SB204 in the treatment of acne vulgaris. In the ... 
01/17/17Novan Licenses SB204 to Sato for Acne in Japan
MORRISVILLE, N.C., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. (“Sato”), a Japanese company with a prescription pharmaceutical business specializing in dermatology. Upon execution of the agreement, Sato will pay to Novan an initial payment of 1.25 billion JPY (approximately $11.0 million) for the exclusive rights to develop and commercia...